EN DE
Watch Seach Medical Group Ltd for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Seach Medical Group Ltd (SEMG) fair value: what the stock is really worth

As of Nov 19, 2026: fair value (intrinsic value) of Seach Medical Group Ltd stock ILS 5.26, price ILS 2.65, upside +98.5%, quality 64 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare Il · ISIN IL0002490113

SM Seach Medical Group Ltd logo Thin data Nov 17, 2026

Seach Medical Group Ltd

SEMG · TA

Cheap (50% below fair value), solid company and rising price: meets all 3 rules.

Follow free in the weekly email
Fair value 5.26 ILS · Strongly undervalued 
Quality 64/100 
Rising price (uptrend) 
Generates free cash flow 
6.8% dividend yield · Sustainable
Ranks above peers (9/13) 
Even on cautious assumptions the value is 36% above the price (3.60 ILS). 
Mixed Growth (revenue 5y +33.7 %/yr in ILS) 
Thin margins · 4.5% net margin (TTM) 
Changed on Oct 25: ILS 2.14 → ILS 5.26 
Narrow moat 35/100 · thin data
Thin data 
Watch Seach Medical Group Ltd for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

4.48 ILS 1.14 ILS Fair Value 5.26 ILS Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.

How to read this chart

60‑month range 1.14 ILS – 4.48 ILS · fair‑value band 3.60 ILS – 6.92 ILS · the 2.65 ILS price screens below the 5.26 ILS fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 17, 2026.

Follow Seach Medical Group in your weekly email

Every Wednesday you see whether Seach Medical Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Seach Medical Group Ltd manufactures and sells medicinal cannabis products worldwide. The company provides cannabis oil and medical cannabis inflorescence products. Seach Medical Group Ltd was incorporated in 1987 and is based in Ramat Gan, Israel.

Stock analysis

Seach Medical Group Ltd (SEMG) currently trades at 2.65 ILS, while our model-based Fair Value estimate is 5.26 ILS, implying the stock looks roughly 50% undervalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of 11.68 ILS per share, and 16 of the 26 models we run sit above the 2.65 ILS price.

Bear case: the Asset-Based group reads lowest at 1.46 ILS, and 10 of the 26 models stay below the price. Data coverage for this calculation is low.

Scenario range: 3.60 ILS (bear) to 6.92 ILS (bull), the price of 2.65 ILS sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 64/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Seach Medical Group Ltd reported revenue of 157M ILS in FY2025 versus 67.3M ILS in FY2021, a compound +23.6%/yr. Reported net income was 1.5M ILS in FY2025, compounding −26.9%/yr from FY2021.

Key figures

Market cap 87.7M ILS Micro · P/E ratio 13.7 · P/S ratio 0.57 · EPS (TTM) 0.1930 ILS · Dividend yield 6.8% · Net margin 4.5% · Return on equity 5.5% · Return on assets (EBIT) 5.0% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 35 out of 100 (low confidence).

What moves the price

The share trades about 16% below its 52-week high and 23% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 99%, SEMG screens cheaper than that median.

Fair Value models

Bear 3.60 ILS Fair Value 5.26 ILS Bull 6.92 ILS
Price 2.65 ILS · Upside +98.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 11 months old). Earnings retained since then (0.0115 ILS per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income 1.70 ILS 1.74 ILS 1.83 ILS 74
FCF DCF 7.81 ILS 11.62 ILS 23.24 ILS 72
Growth DCF 7.34 ILS 13.16 ILS 22.41 ILS 71
All 26 models by family
DCF Models
FCF DCF 7.81 ILS 11.62 ILS 23.24 ILS 72
Owner Earnings 3.46 ILS 7.15 ILS 14.33 ILS 66
5Y Revenue Exit 5.49 ILS 8.93 ILS 16.09 ILS 65
5Y EBITDA Exit 6.64 ILS 11.25 ILS 20.28 ILS 67
5Y P/E Exit 3.07 ILS 4.75 ILS 6.74 ILS 66
10Y Revenue Exit 6.13 ILS 12.17 ILS 15.72 ILS 62
10Y EBITDA Exit 7.08 ILS 14.52 ILS 27.18 ILS 60
10Y P/E Exit 4.60 ILS 7.20 ILS 10.79 ILS 59
Earnings-Based
Graham-Dodd 0.3100 ILS 2.18 ILS 3.06 ILS 61
Lynch FV 1.21 ILS 1.73 ILS 2.25 ILS 59
PEG = 1.0 1.21 ILS 1.73 ILS 2.25 ILS 55
EPV 2.96 ILS 3.36 ILS 3.70 ILS 70
Dividend Discount
Gordon GGM 1.00 ILS 1.90 ILS 2.75 ILS 65
DDM Multi-Stage 1.00 ILS 1.68 ILS 2.02 ILS 65
Multiples
P/E Multiple 0.7600 ILS 1.01 ILS 1.27 ILS 63
P/S Multiple 0.5900 ILS 0.7800 ILS 0.9800 ILS 58
P/B Multiple 7.63 ILS 10.18 ILS 12.72 ILS 55
EV/EBIT 5.15 ILS 6.96 ILS 8.76 ILS 63
EV/EBITDA 5.48 ILS 7.39 ILS 9.30 ILS 64
EV/Revenue 3.60 ILS 5.26 ILS 6.92 ILS 51
Asset-Based
NCAV (Graham) 0.9600 ILS 1.46 ILS 1.83 ILS 52
Growth DCF
Growth DCF 7.34 ILS 13.16 ILS 22.41 ILS 71
Rev-Margin DCF 6.02 ILS 10.19 ILS 18.94 ILS 65
Economic Profit
Residual Income 1.70 ILS 1.74 ILS 1.83 ILS 74
ROIC Compounder 3.27 ILS 4.34 ILS 5.31 ILS 68
Growth Earnings
Growth-Adj P/E 1.50 ILS 2.14 ILS 2.78 ILS 65

Open the full fair value analysis →

Quality Score breakdown

Overall quality 64/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 41
How much profit the company makes from its sales and capital
Quality Growth 17
Are margins and returns getting better?
Cashflow 73
Do the profits arrive as real cash?
Financial strength 72
Debt, balance sheet and risk of trouble
Investment 98
Does it invest with discipline instead of growing at any price?
Low Volatility 67
How calm the share price moves, does not count
Price momentum 45
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 47
Distance to the 52-week high, does not count
New shares 93
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 84/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−8.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+33.7%
Start year 2020 (pandemic). Over 10 years: +54.7% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+53.5%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−22.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year−29.6%
Dividend (yield on the price)6.8%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−29.6% vs −44.3%, picking up
Profit margin 2019 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 9%
Pace: the 5-year rate starts in 2020 (pandemic)
⚠ Revenue per share shrinking 46.5%/yr over ~10Y (margin trend unclear) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−19.7%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Israel: IMF forecast 2.1% a year to 2030, 1.7% from 2016 to 2025) that is about −21.4% a year for the price.

Watch SEMG, get fair value alerts →

Compare Seach Medical Group Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 608 stocks

Beats the industry median on 9/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 64 · Top 25%
Fair Value upside +98.5% · Top 25%
Profitability
Return on equity (12 months) 5.5% · Below median
Return on assets 1.1% · Below median
Net margin (12 months) 4.5% · Below median
Operating margin (12 months) 16.9% · Above median
Growth and dividend
Revenue growth (quarter YoY) −7.3% · Below median
Dividend yield (12 months) 6.8% · Top 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (12 months) 13.7× · Cheaper than median
P/B 0.98× · Cheapest 25%
P/S (12 months) 0.57× · Cheapest 25%
Price / free cash flow (fiscal year) 5.7× · Cheapest 25%
EV/EBITDA 4.3× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 20
FUTURE (revenue growth)0 · sector 29
PAST (return on equity)22 · sector 26
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)100 · sector 33

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $85.57 $113.53 +33% vs SEMG
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥46.88 ¥52.43 +12% vs SEMG
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,900 ₹1,983 +4% vs SEMG
Haleon plc HLN $9.08 $8.47 −7% vs SEMG
Merck KGaA MRK €148.40 €108.83 −27% vs SEMG
Galderma Group GALD CHF 184.70 CHF 112.46 −39% vs SEMG
Takeda Pharmaceutical Company TAK $21.27 $11.23 −47% vs SEMG
Sandoz Group SDZ CHF 81.24 CHF 41.06 −49% vs SEMG
Teva Pharmaceutical Industries Limited TEVA $42.23 $20.74 −51% vs SEMG
Divi's Laboratories Limited DIVISLAB ₹11,178 ₹1,567 −86% vs SEMG

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Seach Medical Group Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Seach Medical Group Ltd Fair Value". https://www.fairvalue-calculator.com/stock/SEMG

Frequently asked questions

Is Seach Medical Group Ltd (SEMG) overvalued or undervalued?
As of Nov 17, 2026, our model estimates a fair value of 5.26 ILS versus a price of 2.65 ILS, about +99% upside (undervalued).
What is the fair value of SEMG?
Our model-based fair value for Seach Medical Group Ltd is 5.26 ILS (as of Nov 17, 2026), built from audited fundamentals. The current price: 2.65 ILS.
What is the quality score of SEMG?
Seach Medical Group Ltd has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Seach Medical Group Ltd (SEMG)?
We do not set a price target; the yardstick is the fair value of 5.26 ILS (as of Nov 17, 2026) from 26 valuation models. Cautious scenario 3.60 ILS, optimistic scenario 6.92 ILS. It is a calculation from audited fundamentals, not an analyst target.
What is the Seach Medical Group Ltd stock forecast for 2026?
Our models put fair value at 5.26 ILS, about +99% upside versus a price of 2.65 ILS (undervalued). Cautious scenario 3.60 ILS, optimistic scenario 6.92 ILS. The calculation is refreshed regularly with new filings.
What is the revenue of Seach Medical Group Ltd (SEMG)?
Seach Medical Group Ltd reported trailing-twelve-month revenue of about 154M ILS (latest available figure, as of Nov 17, 2026).
Does Seach Medical Group Ltd pay a dividend?
Seach Medical Group Ltd currently shows a dividend yield of 6.79% relative to its recent price (as of Nov 17, 2026).
How much is the dividend of Seach Medical Group Ltd (SEMG) and when is the ex-dividend date?
Seach Medical Group Ltd pays a dividend of 0.18 ILS per share a year, a dividend yield of 6.8%. The last ex-dividend date was Apr 9, 2026. The payout ratio is 93.3% of earnings. Free cash flow covers the dividend 2.60 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into Seach Medical Group Ltd (SEMG)?
Today's price is already fair in a discounted-cash-flow model if free cash flow at Seach Medical Group Ltd shrinks by 19.7 % per year for five years (discount rate 10.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 33.7 % per year. As of Nov 17, 2026.
What discount rate (WACC) does the fair value of SEMG use?
Our models discount Seach Medical Group Ltd at 10.1 %: a base by market capitalisation (nano), damped by beta 0.25, country premium for Israel. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Seach Medical Group Ltd that is -19.7 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.1 %) and the same formula as our fair value.
How much growth has Seach Medical Group Ltd (SEMG) delivered so far?
Over the past 5 years revenue at Seach Medical Group Ltd grew 33.7 % a year. The price currently implies free-cash-flow growth of -19.7 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Seach Medical Group Ltd (SEMG) growing?
The median revenue growth in the sector is +7.4 % a year. That is the yardstick for the growth priced into Seach Medical Group Ltd (-19.7 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Seach Medical Group Ltd (SEMG)?
The free-cash-flow yield on the price is 17.68 %: that much free cash flow Seach Medical Group Ltd produces per unit of market value. When it exceeds the discount rate of our models (10.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Seach Medical Group Ltd (SEMG)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Seach Medical Group Ltd it is 5.26 ILS per share (as of Nov 17, 2026), against a price of 2.65 ILS. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Seach Medical Group Ltd stock overvalued or undervalued in 2026?
As of Nov 17, 2026, SEMG trades below its calculated fair value: price 2.65 ILS, fair value 5.26 ILS, a gap of about +99% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SEMG?
No. The price is what the market pays today (2.65 ILS); the fair value is what the company's own numbers justify (5.26 ILS). For Seach Medical Group Ltd the two are 2.61 ILS per share apart. That gap is exactly why we show both numbers side by side.
How much is Seach Medical Group Ltd worth?
The market values Seach Medical Group Ltd at about 87.7M ILS (market capitalisation, as of Nov 17, 2026). Per share that is 2.65 ILS; our models calculate a fair value of 5.26 ILS per share.
What do the bullish and bearish scenarios say about SEMG?
Our models span a range for Seach Medical Group Ltd: cautious scenario 3.60 ILS, base 5.26 ILS, optimistic 6.92 ILS per share (as of Nov 17, 2026, price 2.65 ILS). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SEMG?
Seach Medical Group Ltd trades at a price-to-earnings ratio of 13.7 (as of Nov 17, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 5.26 ILS is built from several models across several years. Other multiples: P/B 1.0, P/S 0.6, EV/EBITDA 4.3.
How solid is the balance sheet of Seach Medical Group Ltd (SEMG)?
Balance-sheet figures for Seach Medical Group Ltd (as of Nov 17, 2026): return on equity 5.5%. They feed the Quality Score of 64/100, which measures business quality independently of the share price.
How far is SEMG from its 52-week high?
Seach Medical Group Ltd trades at 2.65 ILS, about 16% below its 52-week high of 3.14 ILS and 23% above the low of 2.15 ILS (as of Nov 19, 2026). Distance from the high says nothing about value: that is what the fair value of 5.26 ILS is for.
Which stocks are comparable to Seach Medical Group Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Seach Medical Group Ltd stock attractive at the current price?
The data as of Nov 17, 2026: price 2.65 ILS, calculated fair value 5.26 ILS (+99%), Quality Score 64/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SEMG calculated?
We run Seach Medical Group Ltd through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 5.26 ILS builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 12.0% above its aggregate fair value. Seach Medical Group Ltd currently trades 50% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Seach Medical Group Ltd (SEMG)?
The closing price on Nov 19, 2026 was 2.65 ILS. Our model-based fair value is 5.26 ILS, about +99% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Seach Medical Group Ltd right now?
The price is below even our cautious bear case (3.60 ILS). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (64/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (3.60 ILS to 6.92 ILS) leaves room in how you read the outcome.

Key figures of Seach Medical Group Ltd

How large is the market capitalisation of Seach Medical Group Ltd (SEMG)?
The market capitalisation of Seach Medical Group Ltd is 87.7M ILS. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Seach Medical Group Ltd (SEMG)?
The price-to-sales ratio of Seach Medical Group Ltd is 0.57 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Seach Medical Group Ltd (SEMG)?
Earnings per share at Seach Medical Group Ltd are 0.1930 ILS (price ÷ EPS = P/E 13.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Seach Medical Group Ltd (SEMG)?
The dividend yield of Seach Medical Group Ltd is 6.8% (payout 93.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Seach Medical Group Ltd (SEMG)?
The net margin of Seach Medical Group Ltd is 4.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Seach Medical Group Ltd (SEMG)?
The return on equity (ROE) of Seach Medical Group Ltd is 5.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Seach Medical Group Ltd (SEMG)?
On an EBIT basis the return on assets of Seach Medical Group Ltd is 5.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Seach Medical Group Ltd (SEMG)?
The operating margin of Seach Medical Group Ltd is 16.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Seach Medical Group Ltd (SEMG)?
Revenue at Seach Medical Group Ltd is down 7.3% versus a year earlier (3y avg +5.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Seach Medical Group Ltd (SEMG)?
Earnings per share at Seach Medical Group Ltd are growing 44.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Seach Medical Group Ltd (SEMG) carry?
The net debt of Seach Medical Group Ltd is 8.7M ILS (fiscal year 2025, ≈ 0.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Seach Medical Group Ltd in the live analysis

One click puts Seach Medical Group Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.